Literature DB >> 24055088

Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation.

Nikolaos Kotsopoulos1, Mark P Connolly, Maarten J Postma, Raymond C W Hutubessy.   

Abstract

Changes in population health status are known to influence government fiscal transfers both in terms of lost tax revenue and increased expenditure for health and social services. To estimate the fiscal impact of changes in morbidity and mortality attributed to rotavirus immunisation, we developed a government perspective model to estimate discounted net tax revenue for Ghana and Vietnam. The model derived the impact of rotavirus morbidity and mortality on lifetime productive capacity and related tax transfers, and demand for government transfers in relation to education and healthcare in immunised and non-immunised cohorts. The discounted age-specific net tax revenue was derived by deducting transfers from gross taxes and discounting for time preference. In Ghana, taking into account immunisation costs, tax and transfers, the estimated net discounted tax for the immunised cohort was estimated to generate $2.6 billion in net taxes up to age 65. In Vietnam, the net revenue attributed to the immunised cohort reached $55.17 billion suggesting an incremental benefit of approximately $29 million. We posit that the government perspective fiscal framework described here is a valid approach for estimating how governments benefit from investments in immunisation that can be considered supplementary to conventional cost-effectiveness approaches for defining value.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Keywords:  Developing countries; Fiscal analysis; Immunisation; Population health; Rotavirus; Vaccines

Mesh:

Substances:

Year:  2013        PMID: 24055088     DOI: 10.1016/j.vaccine.2013.09.002

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

Review 1.  Economics and financing of vaccines for diarrheal diseases.

Authors:  Sarah M Bartsch; Bruce Y Lee
Journal:  Hum Vaccin Immunother       Date:  2014-04-22       Impact factor: 3.452

Review 2.  Valuing vaccination.

Authors:  Till Bärnighausen; David E Bloom; Elizabeth T Cafiero-Fonseca; Jennifer Carroll O'Brien
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

Review 3.  Systematic review of the economic value of diarrheal vaccines.

Authors:  Richard Rheingans; Mirna Amaya; John D Anderson; Poulomy Chakraborty; Jacob Atem
Journal:  Hum Vaccin Immunother       Date:  2014-05-27       Impact factor: 3.452

4.  Assessment of the Broader Economic Consequences of HPV Prevention from a Government-Perspective: A Fiscal Analytic Approach.

Authors:  Didik Setiawan; Nikolaos Kotsopoulos; Jan C Wilschut; Maarten J Postma; Mark P Connolly
Journal:  PLoS One       Date:  2016-08-04       Impact factor: 3.240

Review 5.  3. How comprehensive can we be in the economic assessment of vaccines?

Authors:  Baudouin Standaert; Rino Rappuoli
Journal:  J Mark Access Health Policy       Date:  2017-08-31

Review 6.  2. How is the economic assessment of vaccines performed today?

Authors:  Baudouin Standaert; Rino Rappuoli
Journal:  J Mark Access Health Policy       Date:  2017-08-31

Review 7.  How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future.

Authors:  Baudouin Standaert; Christophe Sauboin; Rodrigo DeAntonio; Alen Marijam; Jorge Gomez; Lijoy Varghese; Sharon Zhang
Journal:  J Mark Access Health Policy       Date:  2020-01-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.